beeldscherm schreef op 19 juni 2018 11:54:
China Biologic may be too rich for CITIC's blood
June 19, 2018
HONG KONG, June 19 (Reuters Breakingviews) - CITIC Capital is proposing a risky infusion. The buyout arm of the Beijing-based bank offered to take private Nasdaq-listed plasma maker China Biologic Products for $3.7 billion. It's an odd time to offer a 34 percent premium: Healthcare reforms are squeezing the blood business.
In 2016, for example, the pricing system was adjusted in a way that forced producers to spend more on sales and marketing. Hospitals also have had pharmaceutical sales capped at 30 percent of total revenue, thus dampening their appetite for pricier plasma products.
Healthcare reforms are squeezing the blood business.......en
thus dampening their appetite for pricier plasma products.
mooi he...